Philip Jarvis

Trials to assess equivalence: the importance of rigorous methods: Fig 1

Byron Jones, Philip Jarvis, John A. Lewis et al. · BMJ · 1996 · 1K citations

Medicine, Biostatistics, Clinical Pharmacology +13

β-Defensin 2 is a responsive biomarker of IL-17A–driven skin pathology in patients with psoriasis

Frank Kolbinger, Christian Loesche, Marie‐Anne Valentin et al. · Journal of Allergy and Clinical Immunology · 2016 · 234 citations · Full text

Medicine, Dermatology, Immunology +17

Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI-positive cells in the skin

Martin Metz, Petra Staubach, Andrea Bauer et al. · Theranostics · 2017 · 135 citations · Full text

Life Sciences, Dermatology, Immunology +17

The Concordance between Nonclinical and Phase I Clinical Cardiovascular Assessment from a Cross-Company Data Sharing Initiative

Lorna Ewart, Mike Aylott, Mark Deurinck et al. · Toxicological Sciences · 2014 · 77 citations

Pharmacy, Pharmacology, Translational Sciences +17

The cynomolgus monkey as a model for developmental toxicity studies: variability of pregnancy losses, statistical power estimates, and group size considerations

Philip Jarvis, Shiela Srivastav, Elvira Vogelwedde et al. · Birth Defects Research Part B Developmental and Reproductive Toxicology · 2010 · 69 citations

Pharmacy, Obstetrics, Toxicology +14